-
[show abstract]
[hide abstract]
ABSTRACT: MUTYH-associated polyposis (MAP) was first described in 2002. MUTYH is a component of a base excision repair system that protects the genomic information from oxidative damage. When the MUTYH gene product is impaired by bi-allelic germline mutation, it leads to the mutation of cancer-related genes, such as the APC and/or the KRAS genes, via G to T transversion. MAP is a hereditary colorectal cancer syndrome inherited in an autosomal-recessive fashion. The clinical features of MAP include the presence of 10-100 adenomatous polyps in the colon, and early onset of colorectal cancer. Ethnic and geographical differences in the pattern of the MUTYH gene mutations have been suggested. In Caucasian patients, c.536A>G (Y179C) and c.1187G>A (G396D) mutations are frequently detected. In the Asian population, Y179C and G396D are uncommon, whereas other variants are suggested to be the major causes of MAP. We herein review the literature on MUTYH-associated colorectal cancer and adenomatous polyposis.
Surgery Today 04/2013; · 1.22 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Esophageal cancer is the eighth most common form of cancer worldwide. The treatments for esophageal cancer depend on its etiology. For mucosal cancer, endoscopic mucosal resection and endoscopic submucosal dissection are standard, while for locally advanced cancer, esophagectomy remains the mainstay. The three most common techniques for thoracic esophagectomy are the transhiatal approach, the Ivor Lewis esophagectomy (right thoracotomy and laparotomy), and the McKeown technique (right thoracotomy followed by laparotomy and neck incision with cervical anastomosis). Surgery for carcinoma of the cervical esophagus requires an extensive procedure with laryngectomy in many cases. When the tumor is more advanced, neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy is added. The theoretical advantages of adding chemotherapy to the treatment of esophageal cancer are potential tumor down-staging prior to surgery, as well as targeting micrometastases and, thus, decreasing the risk of distant metastasis. Cisplatin- and 5-fluorouracil-based regimes are used worldwide. Chemoradiotherapy is the standard for unresectable esophageal cancer and could also be considered as an option for resectable tumors. For patients who are medically or technically inoperable, concurrent chemoradiotherapy should be the standard of care. Although neoadjuvant chemoradiotherapy followed by surgery or salvage surgery after definitive chemoradiotherapy is a practical treatment; judicious patient selection is crucial. It is important to have a thorough understanding of these therapeutic modalities to assist in this endeavor.
General Thoracic and Cardiovascular Surgery 04/2013;
-
Akihiko Sano,
Shinji Sakurai,
Hiroyuki Kato,
Shigemasa Suzuki,
Takehiko Yokobori,
Makoto Sakai,
Naritaka Tanaka,
Takanori Inose,
Makoto Sohda, Masanobu Nakajima,
Yasuyuki Fukai,
Tatsuya Miyazaki,
Hitoshi Ojima,
Yoshinori Hosoya,
Takehiko Enomoto,
Tatsuo Kanda,
Yoichi Ajioka,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: Esophageal carcinosarcoma (ECS) is a rare malignant neoplasm associated with a poor patient prognosis. It is characterized by the presence of both malignant epithelial and mesenchymal components. Molecular-targeted therapy of several receptor tyrosine kinases (RTKs) has been reported to be effective in the treatment of various malignant tumors, including carcinosarcoma of several organs. This study aimed to assess the therapeutic potential of targeting RTKs in ECS. Overexpression of RTKs was assessed in 21 ECS cases by immunohistochemistry (IHC). Positively stained cases were further examined for RTK gene mutations and amplifications by direct sequencing analysis and fluorescence in situ hybridization. In epithelial components, KIT, platelet-derived growth factor receptor (PDGFR)A, PDGFRB, MET, epidermal growth factor receptor (EGFR) and HER-2 were overexpressed in 1 (4.8%), 1 (4.8%), 0 (0%), 11 (52.4%), 13 (61.9%) and 2 (9.5%) cases, respectively. In the mesenchymal components the corresponding numbers of cases were 2 (9.5%), 2 (9.5%), 0 (0%), 12 (57.1%), 11 (52.4%) and 0 (0%). No mutations in the c-kit, PDGFRA and c-met genes were found. Among 19 EGFR-positive tumors, 2 had EGFR missense mutations (T790A, exon 20) only in the mesenchymal component. Gene amplification or high polysomy of c-kit, PDGFRA, c-met and EGFR was observed in 1 (33.3%), 0 (0%), 3 (18.8%) and 10 (52.6%) cases, respectively. In conclusion, various RTKs, particularly MET and EGFR were overexpressed in ECSs suggesting that molecular-targeted therapies directed to MET, EGFR or other RTKs may be effective in inhibiting the growth or progression of the epithelial and/or mesenchymal component of ECS.
Oncology Reports 03/2013; · 1.84 Impact Factor
-
Tatsuya Miyazaki,
Makoto Sohda,
Naritaka Tanaka,
Shigemasa Suzuki,
Keisuke Ieta,
Makoto Sakai,
Akihiko Sano,
Takehiko Yokobori,
Takanori Inose, Masanobu Nakajima,
Minoru Fukuchi,
Hitoshi Ojima,
Hiroyuki Kato,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: More effective protocols are needed for unresectable and recurrent esophageal cancer. Therefore, we conducted a phase I trial to establish the recommended dose of docetaxel, nedaplatin, and 5-fluorouracil (DNF) as combination chemotherapy. Fourteen patients with esophageal cancer were enrolled and received DNF combination therapy at different dose levels according to the treatment and examination plan. Dose-limiting toxicities (DLTs) included febrile neutropenia. DLTs occurred in 3/5 patients at level 4. The recommended doses (level 3) of DNF were 60 mg/m(2) (day 1), 70 mg/m(2) (day 1), and 700 mg/m(2) (days 1-5), respectively, given at 3-week intervals. In conclusion, DNF combined chemotherapy for advanced esophageal cancer was associated with relatively minor adverse events and was safely administered at the recommended dose. A phase II study is now underway.
Cancer Chemotherapy and Pharmacology 01/2013; · 2.83 Impact Factor
-
Tatsuya Miyazaki,
Takanori Inose,
Naritaka Tanaka,
Takehiko Yokobori,
Shigemasa Suzuki,
Daigo Ozawa,
Makoto Sohda, Masanobu Nakajima,
Minoru Fukuchi,
Hiroyuki Kato,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: Barrett's esophagus (BE) is the premalignant lesion from which esophageal adenocarcinoma near the esophagogastric junction arises. The management of BE and the treatment of Barrett's esophageal adenocarcinoma (BEA) are important clinical issues in Europe and the United States. As the Helicobacter pylori infection rate in Japan is decreasing in the younger population, the incidence of BE and adenocarcinoma arising from BE may start increasing. Thus, we review the current status of BEA and its management. Magnifying endoscopy with narrow-band imaging is important for diagnosing dysplasia arising from BE. In Japan, adenocarcinoma arising from BE is managed the same way as squamous cell carcinoma in the same location. Strategies to prevent BEA may include medication such as non-steroidal anti-inflammatory drugs and proton pump inhibitors, and anti-reflux surgery. Understanding the pathophysiology of BE will help to reduce the incidence of BEA.
Surgery Today 01/2013; · 1.22 Impact Factor
-
Takehiko Yokobori,
Shigemasa Suzuki,
Naritaka Tanaka,
Takanori Inose,
Makoto Sohda,
Akihiko Sano,
Makoto Sakai, Masanobu Nakajima,
Tatsuya Miyazaki,
Hiroyuki Kato,
Hiroyuki Kuwano
Cancer Science 01/2013; 104(1):Januarycover. · 3.33 Impact Factor
-
Takanori Inose,
Tatsuya Miyazaki,
Shigemasa Suzuki,
Naritaka Tanaka,
Makoto Sakai,
Akihiko Sano,
Takehiko Yokobori,
Makoto Sohda, Masanobu Nakajima,
Minoru Fukuchi,
Hiroyuki Kato,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: PURPOSE: Nonspecific esophageal motility disorder (NEMD) is a vague category that includes patients with poorly defined contraction abnormalities observed during esophageal manometry. This study investigated the therapeutic effects of the video-assisted thoracoscopic surgery (VATS) approach using long myotomy and fundopexy for NEMD. METHODS: The VATS approach using myotomy and fundopexy was performed for 4 patients of NEMD between 2005 and 2008. A total of 4 patients with NEMD that underwent treatment at our institution were analyzed retrospectively. RESULTS: The patients included 2 males and 2 females with a median age of 48 years (range 21-74 years). The median duration of NEMD symptoms was 58 months (range 4-108 months). Dysphagia was a primary symptom in all patients. Chest pain was a primary symptom in 3 of 4 patients (75 %). Treatment with medication was attempted before the operation. The median operative time was 344.5 min (range 210-476 min). The median time before starting oral feeding was 2.5 days (range 2-22 days). All patients achieved a significant improvement of their previous condition. CONCLUSIONS: The VATS approach using myotomy and fundopexy for NEMD is a good treatment in cases resistant to medication and balloon dilation.
Surgery Today 12/2012; · 1.22 Impact Factor
-
Masakazu Takahashi, Masanobu Nakajima,
Hideo Ogata,
Yasushi Domeki,
Kichiro Ohtsuka,
Keisuke Ihara,
Eigo Kurayama,
Satoru Yamaguchi,
Kinro Sasaki,
Kazuto Miyachi,
Hiroyuki Kato
[show abstract]
[hide abstract]
ABSTRACT: Background/Aims: Mortality rates due to gastric cancer are high in Japan. To improve patient prognosis, new biomarkers for diagnosis and treatment are urgently required. In this study we investigated the role of CD24, a cell adhesion glycoprotein implicated in tumor cell proliferation, which is used as a prognostic marker in various cancers. Methodology: We analyzed CD24 expression in 173 gastric adenocarcinomas by immunohistochemistry and compared the data with clinicopathological parameters and patient overall survival. Furthermore, we performed Western blotting analysis of CD24 in six human gastric adenocarcinoma cell lines, Kato III, MKN1, MKN28, MKN45, MKN74, and HGC-27. Results: CD24 up-regulation was significantly correlated with depth of invasion (p=0.005) and pathological high stages (p=0.043). We observed a relationship between high CD24 expression and lymph node metastasis, venous invasion and lymphatic invasion. CD24 expression tended to be higher in cell lines derived from differentiated gastric carcinoma, including those derived from lymph node metastasis. Conclusions: Our study suggests that gastric cancer patients with high CD24 expression should be closely monitored for recurrence following resections. CD24 expression is a potential biomarker for gastric cancer prognosis and provides a new molecular target for therapeutic strategies.
Hepato-gastroenterology 11/2012; 60(124). · 0.66 Impact Factor
-
Takehiko Yokobori,
Shigemasa Suzuki,
Naritaka Tanaka,
Takanori Inose,
Makoto Sohda,
Akihiko Sano,
Makoto Sakai, Masanobu Nakajima,
Tatsuya Miyazaki,
Hiroyuki Kato,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: The association of microRNAs (miRs) with cancer progression has been established in many cancers including esophageal squamous cell carcinoma (ESCC). A public microarray database showed that the expression of miR-150 was lower in ESCC than in normal esophageal mucosa. Here, we focused on ZEB1, epithelial-mesenchymal-transition (EMT)-inducers, as target genes of miR-150 based on in silico predictions. The purpose of this study was to clarify the clinicopathological significance of miR-150 in ESCC, and to investigate miR-150's EMT-regulatory ability. Quantitative RT-PCR was used to evaluate miR-150 expression in 108 curative resected ESCC samples to determine the clinicopathological significance. Moreover, we examined the in vitro and in vivo function of miR-150 via degradation of ZEB1. MiR-150 expression was significantly lower in cancer tissues compared to adjacent non-cancerous tissues (p<0.001). Low expression of miR-150 in ESCC contributed to malignant potential, such as tumor depth, lymph node metastasis, lymphatic invasion, venous invasion, clinical staging, and poor prognosis (p<0.05). In vitro assays showed that EMT-inducer-ZEB1 is a new direct target of miR-150. Moreover, miR-150 induced MET-like changes in TE-8 cells through ZEB1 degradation (e.g., E-cadherin expression, vimentin repression, epithelial morphology, and suppression of migration ability), and significantly inhibited tumorigenicity and tumor growth in a mouse xenograft model. Analysis of the regulation of ZEB1 by miR-150 could provide new insights into preventing metastasis and also suggests novel targeted therapeutic strategies in ESCC.
Cancer Science 09/2012; · 3.33 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: (18)F-Fluorodeoxyglucose positron emission tomography has become an important informative modality during the past two decades. Because this type of tomography is a functional imaging construct, its primary use is in the field of oncology. It is being used increasingly in the management of several tumor types including esophageal cancer. These tomography scans can distinguish between benign and malignant tumors, identify stages of tumor spread, assess tumor recurrence, and monitor the response of malignant disease to therapy. The aim of this review was to outline the current and future roles of positron emission tomography in the management of esophageal cancer.
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 06/2012; 18(5):412-9.
-
Shigemasa Suzuki,
Takehiko Yokobori,
Naritaka Tanaka,
Makoto Sakai,
Akihiko Sano,
Takanori Inose,
Makoto Sohda, Masanobu Nakajima,
Tatsuya Miyazaki,
Hiroyuki Kato,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: CD47 inhibits phagocytosis and its overexpression is correlated with poor prognosis in patients with several types of cancer. It has also been reported that CD47 expression in multiple sclerosis is regulated by microRNAs. However, the regulatory mechanism of CD47 in cancer tissues has not been yet clarified. Re-analysis of a public microarray database revealed that miR-133a is downregulated in esophageal squamous cell carcinoma (ESCC). Moreover, in silico algorithms predicted that miR-133a is a regulator of CD47. The purpose of this study was to clarify the clinical significance of CD47 and its regulatory mechanism by miR-133a in ESCC. Quantitative real-time RT-PCR was used to evaluate CD47 and miR-133a expression in 102 cases of curative resected ESCC and adjacent non-cancerous tissue. The regulation of CD47 by miR-133a was examined with precursor miR-133a-transfected cells. A mouse xenograft model was used to investigate the ability of miR-133a to suppress tumor progression. High expression levels of CD47 were associated with lymph node metastasis (P=0.049). Multivariate analysis showed that CD47 expression was an independent prognostic factor (P=0.045). miR-133a expression was significantly lower in cancer tissues compared to adjacent non-cancerous tissues (P<0.001). In vitro assays showed that miR-133a is a direct regulator of CD47. miR‑133a significantly inhibited tumorigenesis and growth in vivo. CD47 expression is a novel prognostic marker in ESCC that is directly inhibited by the miR-133a tumor suppressor. This correlation could provide new insight into the mechanism of cancer progression and a promising candidate for target therapy in ESCC.
Oncology Reports 05/2012; 28(2):465-72. · 1.84 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Extranodal invasion (ENI) has been reported to be associated with a poor prognosis in several malignancies. However, previous studies have included perinodal fat tissue tumor deposits in their definitions of ENI. To investigate the precise nature of ENI in esophageal squamous cell carcinoma (ESCC), we excluded these tumor deposits from our definition of ENI and defined tumor cell invasion through the lymph node capsule and into the perinodal tissues as lymph node capsular invasion (LNCI). The aim of the current study was to elucidate the significance of LNCI in ESCC.
We investigated the associations between LNCI and other clinicopathologic features in 139 surgically resected ESCC. We also investigated the prognostic significance of LNCI in ESCC.
LNCI was detected in 35 (25.2%) of 139 patients. The overall survival rate of the ESCC patients with LNCI was significantly lower than that of the ESCC patients with lymph node metastasis who were negative for LNCI. The survival difference between the patients with 1–3 lymph node metastases without LNCI and those with no lymph node metastasis was not significant. LNCI was significantly associated with distant organ recurrence. LNCI was also found to be an independent predictor of overall survival in addition to the number of lymph node metastases.
LNCI in ESCC patients is an indicator of distant organ recurrence and a worse prognosis. LNCI could be used as a candidate marker for designing more precise staging and therapeutic strategies for ESCC.
Annals of Surgical Oncology 01/2012; 19(6):1911-7. · 4.17 Impact Factor
-
Masanobu Nakajima,
Hiroyuki Kato,
Tatsuya Miyazaki,
Minoru Fukuchi,
Norihiro Masuda,
Yasuyuki Fukai,
Makoto Sohda,
Takanori Inose,
Makoto Sakai,
Akihiko Sano,
Naritaka Tanaka,
Faried Ahmad,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: Heat shock proteins (HSPs) are well known as tumor rejection antigens, most notable of which is HSP70. HSP110 is classified as a member of the HSP70/DnaK superfamily. The objective of this study was to clarify the clinicopathological and prognostic significance of Heat Shock Protein 110 expression and T lymphocyte infiltration in esophageal cancer.
Immunohistochemical staining of HSP110, CD4 and CD8 were performed on surgical specimens obtained from 124 patients with esophageal cancer.
The expression of HSP110 correlated inversely with depth of invasion (p<0.0001), lymph node metastasis (p=0.0163), pathological stage (p<0.0001), lymphatic invasion (p=0.0104), blood vessel invasion (p=0.0027), infiltrative growth pattern (p=0.0368) and correlated positively with CD4+ T lymphocyte infiltration (p=0.0018). Reduction of HSP110 expression was significantly correlated with poor prognosis (p=0.0010).
The present findings suggest that HSP110 expression and T lymphocyte infiltration is a significant prognostic factor for esophageal cancer.
Hepato-gastroenterology 11/2011; 58(110-111):1555-60. · 0.66 Impact Factor
-
Tatsuya Miyazaki,
Naritaka Tanaka,
Hanako Hirai,
Takehiko Yokobori,
Akihiko Sano,
Makoto Sakai,
Takanori Inose,
Makoto Sohda, Masanobu Nakajima,
Minoru Fukuchi,
Hiroyuki Kato,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: Ghrelin is a peptide hormone predominantly produced by endocrine cells in the oxyntic mucosa of the stomach and is an endogenous ligand for the growth hormone secretagogue receptor. Ghrelin plays an important role in regulating appetite, food intake, and energy metabolism. We investigated the correlation between clinicopathologic factors and plasma ghrelin concentration before and after esophagectomy with gastric tube reconstruction for esophageal cancer treatment.
The study group comprised 25 patients (22 men, three women, age range 46-78 y) with esophageal cancer who underwent esophagectomy with gastric tube reconstruction between 1999 and 2007. Blood samples were collected before and three times after the operation. Plasma concentrations of ghrelin were determined using a sandwich-type enzyme immunoassay kit.
Plasma ghrelin concentrations were significantly decreased to 38.7% of the preoperative concentration at postoperative d 7. Plasma ghrelin concentrations recovered slightly over 6-24 mo postoperatively. After 36 mo or longer, ghrelin concentrations had returned to preoperative levels. There was no relationship between ghrelin concentrations and gender, location of tumor, tumor stage, operative procedure, and reconstruction route at each time point. There was a significant relationship between the decrease in body mass index and decrease in plasma ghrelin in patients at 6-24 mo after esophagectomy (P < 0.01).
Plasma ghrelin concentrations decrease on a temporary basis after esophagectomy with gastric tube reconstruction and are associated with body weight loss after surgery.
Journal of Surgical Research 10/2011; 176(1):74-8. · 2.25 Impact Factor
-
Masanobu Nakajima,
Hiroyuki Kato,
Hiroto Muroi,
Akira Sugawara,
Miyako Tsumuraya,
Kichiro Otsuka,
Yasushi Domeki,
Shinichi Onodera,
Kinro Sasaki,
Masahiro Tsubaki,
Makoto Sohda,
Tatsuya Miyazaki,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: Granular cell tumors of the esophagus are rare neoplasms and their diagnosis is mainly based on histopathologic examination of endoscopic biopsies. With the development of endoscopic techniques, there has been a marked increase in local treatment modalities for early esophageal neoplasms. In this case report, we describe the removal of a granular cell tumor by the endoscopic submucosal dissection technique, and briefly discuss the literature on clinicopathologic aspects and management of granular cell tumors.
Esophagus 09/2011; 8(3):203-207. · 0.66 Impact Factor
-
Nippon rinsho. Japanese journal of clinical medicine 08/2011; 69 Suppl 6:121-5.
-
Nippon rinsho. Japanese journal of clinical medicine 08/2011; 69 Suppl 6:182-9.
-
Tatsuya Miyazaki,
Makoto Sohda,
Makoto Sakai,
Naritaka Tanaka,
Shigemasa Suzuki,
Takehiko Yokobori,
Takanori Inose, Masanobu Nakajima,
Minoru Fukuchi,
Hiroyuki Kato,
Motoyasu Kusano,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: Esophageal motility disorders are classified primary and secondary, and primary esophageal motility disorders are classified esophageal achalasia and other diseases by manometry. An esophageal emptying disorder associated with insufficient relaxation of the lower esophageal sphincter (LES) and elimination of peristaltic waves on the esophageal body is the major abnormality of achalasia. Esophagogram, endoscopy, and manometry are used for diagnosis. As pharmacological therapy, administration of a calcium channel blocker or nitrate is useful. The pharmacological therapy is not recommended as long-term basic therapy but as a temporary treatment. At 1st, the balloon dilation method is chosen in treatment of achalasia Surgical treatment is indicated in the following cases: (1) Patients uneffected by balloon dilation, (2) Flask type with grade II to III dilation, and sigmoid type, (3) the gradual progression to the pathophysiological stage, (4) young patients, (5) complicated with esophageal cancer. Laparoscopic Heller-Dor procedure is the most popular surgical procedure, recently. It is somewhat difficult to perform surgical treatment for this functional disease. We should select the most suitable individualized treatment with efficient comprehension of the pathophysiological situation.
Kyobu geka. The Japanese journal of thoracic surgery 07/2011; 64(8 Suppl):770-5.
-
[show abstract]
[hide abstract]
ABSTRACT: Esophageal cancer is the 6th most common cancer in Japan. For the early cancer without lymph node metastasis, endoscopic resection is commonly performed. Esophagectomy with 3-field lymphadenectomy is the standard therapy for resectable esophageal cancer (stage I - IV). Chemoradiotherapy (CRT) is the standard therapy for unresectable esophageal cancer and could also be considered as an option for resectable esophageal cancer. The complications of endoscopic resection are stenosis, perforation, pneumomediastinum, and so on. Major surgical complication are anastomotic leakage, recurrent nerve paralysis, heart failure, respiratory insufficiency. The rates of complications increase after salvage operation, therefore, hospital mortality rate is 7-15%. The serious complications of chemoradiotherapy are late pericardial effusion and pleural effusion.
Kyobu geka. The Japanese journal of thoracic surgery 07/2011; 64(8 Suppl):776-81.
-
Makoto Sohda,
Hiroyuki Kato,
Shigemasa Suzuki,
Naritaka Tanaka,
Akihiko Sano,
Makoto Sakai,
Takanori Inose, Masanobu Nakajima,
Tatsuya Miyazaki,
Minoru Fukuchi,
Noboru Oriuchi,
Keigo Endo,
Hiroyuki Kuwano
[show abstract]
[hide abstract]
ABSTRACT: The role and potential usefulness of positron emission tomography (PET) scanning in certain tumors has been widely investigated in recent years. (18)F-FAMT (L-[3-(18)F]-α-methyltyrosine) is an amino acid tracer for PET. This study investigated whether PET/CT with (18)F-FAMT provides additional information for preoperative diagnostic workup of esophageal squamous cell carcinoma compared with that obtained by (18)F-FDG (fluorodeoxyglucose) PET or CT.
PET/CT studies with (18)F-FAMT and (18)F-FDG were performed as a part of the preoperative workup in 21 patients with histologically confirmed esophageal squamous cell carcinoma.
For the detection of primary esophageal cancer, (18)F-FAMT-PET exhibited a sensitivity of 76.2%, whereas the sensitivity for (18)F-FDG-PET was 90.5% (P = 0.214). (18)F-FAMT uptake in primary tumors showed significant correlation with depth of invasion (P = 0.005), lymph node metastasis (P = 0.045), stage (P = 0.031), and lymphatic invasion (P = 0.029). In the evaluation of individual lymph node groups, (18)F-FAMT-PET exhibited 18.2% sensitivity, 100% specificity, 71.9% accuracy, 100% positive predictive value, and 70.0% negative predictive value, compared with 24.2%, 93.7%, 69.8%, 66.6%, and 70.2%, respectively, for (18)F FDG-PET. CT exhibited 39.4% sensitivity, 85.7% specificity, 69.8% accuracy, 59.1% positive predictive value, and 73.0% negative predictive value. The specificity of (18)F-FAMT-PET is significantly higher than that of (18)F-FDG-PET (P = 0.042) and CT (P = 0.002). (18)F-FAMT-PET did not have any false-positive findings compared to those with (18)F-FDG-PET.
Our findings suggest that the addition of (18)F-FAMT-PET to (18)F-FDG-PET and CT would permit more precise staging of esophageal cancer.
Annals of Surgical Oncology 12/2010; 17(12):3181-6. · 4.17 Impact Factor
